Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919642 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
A Phase 2 study, sponsored by TransThera Sciences (Nanjing).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT04919642 is a Phase 2 study that has completed, run by TransThera Sciences (Nanjing). The registered enrollment target is 55 participants.
The verdict
NCT04919642, a Phase 2 study, has completed, sponsored by TransThera Sciences (Nanjing).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
Interventions
- DRUG TT-00420
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919642
The ClinicalTrials.gov registry entry for NCT04919642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TransThera Sciences (Nanjing), which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TT-00420 is the first listed.
NCT04919642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04919642 about?
NCT04919642 is a clinical study titled "Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma". This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
What is the current status of trial NCT04919642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2021-12-07. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT04919642?
The interventions under investigation include: TT-00420 (DRUG).
Who is sponsoring clinical trial NCT04919642?
This trial is sponsored by TransThera Sciences (Nanjing), which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.